NCT03976310 (BenraliScan) is a NA clinical trial of 48 weeks of Benralizumab in Asthma, sponsored by University Hospital, Montpellier.

Who is sponsoring NCT03976310?

NCT03976310 is sponsored by University Hospital, Montpellier.

What drugs are being tested in NCT03976310?

Interventions in NCT03976310: 48 weeks of Benralizumab, Computed tomography.

Is NCT03976310 still recruiting?

NCT03976310 is currently completed. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT03976310: BenraliScan

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients

Completed NA Last updated 18 July 2023

What this trial tests

NA trial testing 48 weeks of Benralizumab in Asthma in 59 participants. Completed in 9 June 2023.

Timeline

20 June 2019

Primary endpoint
9 June 2023

9 June 2023

Quick facts

Lead sponsor	University Hospital, Montpellier
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	59
Start date	20 June 2019
Primary completion	9 June 2023
Estimated completion	9 June 2023
Sites	2 locations across France

Drugs / interventions tested

48 weeks of Benralizumab — full drug profile →
Computed tomography

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

University Hospital, Montpellier

Who can join

Adults 18 to 75, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BenraliScan aims to obtain thoracic computed tomography imaging data to predict the future level of patient response to a monoclonal antibody. Because the clinical responses under study can take many months to manifest, early identification of patients most-likely to benefit from treatment and treatment rule-out for others will save considerable time for everybody involved. The primary objective of BenraliScan is to determine the prognostic value (sensitivity, specificity, positive predictive value, negative predictive value) of air-trapping measures (Expiratory/Inspiratory ratios for Mean Lung Density (MLDe/i)) detected via quantitative thoracic computed tomography at baseline for improvement in exacerbation rate (the presence of a ≥50% reduction in baseline exacerbation rate versus the absence of a ≥50% reduction in baseline exacerbation rate) at 52 weeks among eosinophilic asthma patients treated with Benralizumab.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of Biologic Therapy on the Small Airways Asthma Phenotype.
Chan R, Lipworth BJ. · · 2022 · cited 25× · PMID 36239786 · DOI 10.1007/s00408-022-00579-2
Clinical response progression to benralizumab using computed tomography: Prognostic BenraliScan study.
Bourdin A, Beclin MF, Chanez P, Vachier I, et al · · 2026 · PMID 42106061 · DOI 10.1016/j.chest.2026.04.040

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03976310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03976310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing